Animal Models to Study Amyotrophic Lateral Sclerosis

Subjects: Pathology

Contributor: Marco Milanese

Amyotrophic lateral sclerosis (ALS) is a fatal, multigenic, multifactorial, and non-cell autonomous neurodegenerative disease characterized by upper and lower motor neuron loss. Several genetic mutations lead to ALS development and many emerging gene mutations have been discovered in recent years. Over the decades since 1990, several animal models have been generated to study ALS pathology including both vertebrates and invertebrates such as yeast, worms, flies, zebrafish, mice, rats, guinea pigs, dogs, and non-human primates. Although these models show different peculiarities, they are all useful and complementary to dissect the pathological mechanisms at the basis of motor neuron degeneration and ALS progression, thus contributing to the development of new promising therapeutics.

amyotrophic lateral sclerosis   genetic animal models

1. Introduction

Amyotrophic lateral sclerosis (ALS), also known as Charcot's or Lou Gehrig's disease, is a multisystem neurodegenerative disease, characterized by heterogeneity at the genetic, neuropathological, and clinical levels [1]. The progressive degeneration of upper and lower motoneurons (MNs) occurs during disease progression and affects pyramidal cells in the cortex, the corticospinal tract, and spinal motoneurons, usually sparing the extraocular and sphincter muscles [1][2][3]. The effects of MN loss evolve in muscle weakness, fasciculations, atrophy, spasticity, and hyperreflexia, eventually leading to paralysis, and patients typically die due to respiratory failure within three to five years from diagnosis [4][5]. Early pathogenic processes involve axonal degeneration and impairment of nerve terminal function, anticipating MN loss, and the onset of clinical symptoms [6].

Several causes have been proposed as the basis of the disease onset and progression, such as excessive calcium and glutamate excitotoxicity [7][8][9][10][11][12][13][14], oxidative stress [15][16][17], axonal damage and transport dysfunction [18][19][20][21], neuroinflammation [22][23], proteins misfolding and aggregation [24][25], proteasome impairment [26][27], endoplasmic reticulum stress [28][29], mitochondrial dysfunction and insufficient energy supply [30][31][32], and altered RNA processing [33][34]. Initially, ALS has been considered mostly as a MN disorder, but to date, much evidence confirms that ALS is a non-cell-autonomous disease, involving astrocytes, oligodendrocytes, microglia, and blood-derived immune cells [35][36][37]. Moreover, ALS forms a neurodegenerative disease continuum with frontotemporal dementia (FTD), and up to 50% of ALS patients concomitantly develop cognitive impairment or behavioral changes [38].

Most ALS cases are sporadic (sALS), and up to 10% have been classified as familial ALS (fALS) [39]. Currently, fALS-associated mutations have been found in approximately 50 genes, and more than 30 of them are thought to be causative [40][41]. The most common mutated genes are superoxide dismutase-1 (*SOD1*), chromosome 9 open reading frame 72 (*C9orf72*), fused in sarcoma (*FUS*), and TAR DNA-binding protein (*TARDBP*) [42]. Moreover, a significant fraction (about 20%) of sporadic cases carried a confirmed or likely pathogenic mutation, and almost all had no family history of ALS. This occurrence establishes the importance of routinely performing the genetic sequencing on ALS patients to improve disease subclassification, patient stratification, and clinical care [43].

2. Genes Involved in ALS

Mutations of the gene encoding for Cu/Zn SOD1 are among the most frequent ones in ALS [41]. Since SOD1 catalyzes the dismutation of superoxide anion in oxygen and hydrogen peroxide, the different mutations result in the decrease of free radicals detoxication (loss of function, LoF), but also in a toxic gain of function (GoF; [44]).

Mutations related the *TARDBP* gene, encoding the TAR DNA binding protein 43 (TDP-43), have been also identified in ALS [45]. Mutated TDP43 is indeed the main protein found in protein aggregates in the cytoplasm of MNs [46][47][48], contributing to the alteration of several cellular processes in ALS [49].

Other gene mutations involved in ALS are those related to the *FUS/TLS* gene, encoding for the RNA-binding protein FUS [50][51]. This protein is physiologically located in the nucleus but, when mutated, it aggregates in the cytoplasm of neurons [47][52], leading to cell death [48].

More recently, the repeated expression of hexanucleotide "GGGGCC" (G4C2) in the *C9orf72* gene's non-coding region has been identified in ALS and demonstrated to alter critical cellular processes, including autophagy, membrane trafficking, immune response [53][54][55][56]. It is not yet clear why some patients with *C9orf72* repeat expansion manifest ALS phenotype, while others only FTD or both. Moreover, there is no apparent correlation between repeat size and disease severity [57]. To date, three different hypothetic mechanisms by which this genetic mutation may induce ALS have been hypothesized and none of them are exclusive [58]. The first hypothesis sustains that the repeat expansion may cause C9orf72 LoF, which contributes to neurodegeneration by yet unknown mechanisms. The second hypothesis is related to an RNA toxicity generated by G4C2 repeat-containing RNA foci that accumulate in the nucleus and induce the concomitant entrapment of other RNA-binding proteins that can no longer exert their physiological role. The third possibility deals with the accumulation of sense and antisense repeat proteins in the form of aggregation-prone dipeptide repeats.

All the above gene mutations contribute to ALS development and progression by triggering different toxic processes [59], such as oxidative damage and intracellular protein aggregates [17][60][61][62][63][64], axonal transport impairment [18], mitochondrial dysfunction [65], RNA metabolism impairment [66], and excitotoxicity [7][9][12]. It should also be considered that genetic factors not only affect MNs, but also actively contribute to the degeneration or the activation of other CNS cells such as astrocytes and microglia, leading to neuroinflammation and other pathological phenomena [67].

Yet, there are other less frequent protein mutations involved in familial ALS form, such as: VAMP-associated protein B (VABP), Optineurin (OPTN), Valosin Containing Protein (VCP), Ubiquilin-2 (UBQLN2), Matrin 3 (MATR3), TANK-Binding Kinase-1 (TBK1), NIMA-related Kinase-1NEK1, and C21orf2 mutations [68][69].

Finally, it is important to consider also the interplay between environmental factors and genetic mutations that contributes to further complicate the multifactorial scenario of ALS [70][71].

3. Modelling Human ALS in Living Organisms

Following the continuous identification of mutated genes, many animal models have been developed to unravel the pathological mechanisms that are crucial to MN degeneration. Indeed, the cellular alterations in ALS are likely the result of many different interacting mechanisms leading to a larger network disruption. Modeling ALS as human neurodegenerative disorder into any other species, especially in mammals, is certainly a hard task in terms of face, construct, and predictive validity, and ALS is no exception. Even though the obvious limitations of animal models, and possibly for this very reason, their number is still growing in the attempt to obtain further items to identify adequate targets for the development of effective therapies, which this very complex disease urgently needs [72][73][74][75].

The purpose is to provide a comprehensive and up-to-date overview of the available ALS animal models, with the aim of offering details, including pros and cons, useful to design and optimize preclinical studies to investigate ALS. The researchers examined a variety of experimental models of the disease, from the most used to the least common, based on the ALS genetic mutations and the different organisms in which they have been reproduced. In addition, the researchers have also included some very interesting non-genetic models in which MNs injury is based on autoimmune mechanisms or on the exposure to possible ALS environmental risk factors

4. Conclusions

Although more than 50 disease-modifying drugs with different mechanisms of action have been studied in the last decades, there is an urgent need of effective therapies for ALS. Following the initial discovery of mutations in fALS patients, it was possible to model the human disease in living organisms to elucidate the mechanisms underlying MN death in ALS.

Similarly to human studies, accurate preclinical guidelines for phase-based efficacy evaluation of innovative therapeutic approaches and more transparency in reporting the experiments involving animals [76][77] would produce more reliable results than the majority of the current studies present in the literature. Indeed, the rationale for the choice of a specific ALS model, experimental design details, and access to the data obtained can be very useful to better interpret the results, particularly by clinicians who try to translate into clinical trials the most promising preclinical data.

Here, the researchers provide an overview of the different experimental models, from yeast to non-human primates, to investigate ALS pathophysiology. The researchers clustered these models on a genetic mutation criterion, highlighting the peculiarities and the ALS-related molecular, cellular, and clinical symptoms, also focusing on pros and cons that need to be considered when approaching the study of ALS pathogenesis or new experimental therapies (**Figure 1**). Clearly, the main advantage of in vivo over in vitro studies is the higher chance to clarify the multifaced pathological mechanisms that characterize the human pathology during disease progression. Although a comparative analysis of these models is required to choose the best one(s) required for the planned investigation, if we want to better understand the causes of ALS, we should never forget their limitations.

	Animal species	Genetic & non genetic models	PROS	CONS
	SACCHAROMYCES CEREVISIAE	*SOD1* (1A4V-G39A-G93C-L38V-S134N) *TDP-43* (Q331K-M337V-Q343R-N345K-R361S-N390D) *FUS* (expression of human WT and/or mutated FUS genes) *C9ORF72* (upstream activator sequence GA80-GFP)	Very suitable to study citotoxicities and proteinophaties Many of the complex processes and pathways coupled to protein folding diseases Fast growth Fully sequenced genoma Facilitated genetic manipulation Discete human gene homology (about 20%)	Unicellular organisms Short life span
	C. ELEGANS (WORMS)	*SOD1* (G93A-G37R-1A4V-T70I) *TDP-43* (A315T-G348C-A382T) *FUS* (R495X-H517Q-R521G) *C9ORF72* (upstream activator sequence GA80-GFP)	Easy neuronal system to study Fast life cycle Transparent body High fertility Fully sequenced genoma Human gene homology (about 75%) Low cost maintainance Different transgenic models	Invertebrate and small size Brain and blood absence Short life span for chronic disease
	DROSOPHILA (FRUIT FLIES)	*SOD1* (G93C-G37R-1A4V-G41D-I113T-G85R-1H71Y-1H48R) *TDP-43* (G294A-M337V-D169G-G298S-A315T-M337V-N345K-G287S-G348C-A382T-N390D-Q367X) *FUS* (R518K-R521C-R521G-R521H-R524S-P525L) *C9ORF72* (upstream activator sequence G4C2)	Easy neuronal system to study and molecular pathways similar to humans Fast models of ALS symptoms Fast life cycle High fertility Sequenced genoma Human gene homology (about 75%) Availabiliy of mutagenic and transgenic techniques Low cost maintainance	Invertebrate and small size Nervous system differences respect to humans Short life span for chronic disease
	ZEBRAFISH	*SOD1* (G93A-G37R-1A4V-T70I) *TDP-43* (A315T-G348C-A328T) *FUS* (R495X-H517Q-R521G-R521C) *C9ORF72* (upstream activator sequence GA80-GFP)	Vertebrate Low neuronal system complexity and similarities to humans Long life span for chronic disease High fertility Fully sequenced genoma Human gene homology (about 70%) Availabiliy of mutagenic techniques Low cost maintainance	Small size Lack of upper MNs Intermediate life cycle Low availability of transgenic models
	MOUSE / RAT	*SOD1* (G93A-G37R-G86R-G85R-H46R) *TDP-43* (A315T-M337V-G298S-Q331K-G348C-F210I) *FUS* (R521C, knock-in, AVV9-based over expression) *C9ORF72* (knock-out, knock-in, CRISPR/cas9) *ALS2* (261delA-553delA-G660A-1130delAT) *SEXT* (R2136H-L389S) *OPTN* (Q398X-E478G-D477N-D474N) *UBQLN2* (P497H-P506T-P497S-P497H) *PNF1* (G118V-C71G) *VCP* (R155H-A232E) *VAPB* (P56S-T46I-del160-D130E-A145V-S160Δ-V234I) β-N-methylamino-L-alanine (L-BMAA) model	Vertebrate mammals of midsize Long life span for chronic disease Fully sequenced genoma Human gene homology (about 100%) Nervous system function and molecular pathways similar to humans Availabiliy of mutagenic techniques More information since they are the most used in scientific publications	High maintainance cost and time consuming investigation Ethical issues Low fertility Long life cycle Complex nervous system Low availability of transgenic
	GUINEA PIG	Ascorbic acid deficient diet model Experimental autoimmune gray matter disease Experimental autoimmune motor neuron disease Immunization for choline acetyltransferase	Focus on the autoimmune etiology of ALS Peripheral neuromuscolar symptoms with loss of upper and lower MNs	Difficulties to generate control conditions No possibilities to distinguis fALS and sALS High maintainance cost and time consuming investigation Ethical issues
	CANINE	*SOD1* (T18S-E40K)	Spontaneously occuring disease Human homologous nervous system complexity	Tissue availability only for early disease stages Ethical issues
	SWINE	*SOD1* (G39A) *TDP-43* (M337V)	Anatomical, physiological and biochemical features more closely related to humans Fully sequenced genome Genome size and composition similar to humans Large size	Maintainance cost and time consuming investigation Etichal issues Long life cycle Complex nervous system Low availability of transgenic Long lifespan
	NON HUMAN PRIMATE	*TDP-43* (AAV-based human WT TDP-43 over expression)	Vertebrate mammals with medium or large size Many similarities to humans Fully sequenced genome Human gene homology (about 100%)	High maintainance cost and time consuming investigation Etichal issues Low fertility Long life cycle Complex nervous system Low availability of mutagenic and transgenic techniques Long life span

Figure 1. Pros and cons of available ALS animal models.

References

1. Brown, R.H.J.; Al-Chalabi, A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017, 377, 1602.

2. Hardiman, O.; Al-Chalabi, A.; Chio, A.; Corr, E.M.; Logroscino, G.; Robberecht, W.; Shaw, P.J.; Simmons, Z.; van den Berg, L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 2017, 3, 17085.

3. Štětkářová, I.; Ehler, E. Diagnostics of Amyotrophic Lateral Sclerosis: Up to Date. Diagnostics 2021, 11, 231.

4. Al-Chalabi, A.; Hardiman, O. The epidemiology of ALS: A conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013, 9, 617–628.

5. Taylor, J.P.; Brown, R.H.J.; Cleveland, D.W. Decoding ALS: From genes to mechanism. Nature 2016, 539, 197–206.

6. Dukkipati, S.S.; Garrett, T.L.; Elbasiouny, S.M. The vulnerability of spinal motoneurons and soma size plasticity in a mouse model of amyotrophic lateral sclerosis. J. Physiol. 2018, 596, 1723–1745.

7. Milanese, M.; Zappettini, S.; Onofri, F.; Musazzi, L.; Tardito, D.; Bonifacino, T.; Messa, M.; Racagni, G.; Usai, C.; Benfenati, F.; et al. Abnormal exocytotic release of glutamate in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2011, 116, 1028–1042.

8. Pieri, M.; Caioli, S.; Canu, N.; Mercuri, N.B.; Guatteo, E.; Zona, C. Over-expression of N-type calcium channels in cortical neurons from a mouse model of Amyotrophic Lateral Sclerosis. Exp. Neurol. 2013, 247, 349–358.

9. Bonifacino, T.; Musazzi, L.; Milanese, M.; Seguini, M.; Marte, A.; Gallia, E.; Cattaneo, L.; Onofri, F.; Popoli, M.; Bonanno, G. Altered mechanisms underlying the abnormal glutamate release in amyotrophic lateral sclerosis at a pre-symptomatic stage of the disease. Neurobiol. Dis. 2016, 95, 122–133.

10. Sugiyama, K.; Tanaka, K. Spinal cord-specific deletion of the glutamate transporter GLT1 causes motor neuron death in mice. Biochem. Biophys. Res. Commun. 2018, 497, 689–693.

11. Tedeschi, V.; Petrozziello, T.; Secondo, A. Calcium Dyshomeostasis and Lysosomal Ca(2+) Dysfunction in Amyotrophic Lateral Sclerosis. Cells 2019, 8, 1216.

12. Armada-Moreira, A.; Gomes, J.I.; Pina, C.C.; Savchak, O.K.; Gonçalves-Ribeiro, J.; Rei, N.; Pinto, S.; Morais, T.P.; Martins, R.S.; Ribeiro, F.F.; et al. Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases. Front. Cell. Neurosci. 2020, 14, 90.

13. Milanese, M.; Bonifacino, T.; Fedele, E.; Rebosio, C.; Cattaneo, L.; Benfenati, F.; Usai, C.; Bonanno, G. Exocytosis regulates trafficking of GABA and glycine heterotransporters in spinal cord glutamatergic synapses: A mechanism for the excessive heterotransporter-induced release of glutamate in experimental amyotrophic lateral sclerosis. Neurobiol. Dis. 2015, 74, 314–324.

14. Stifanese, R.; Averna, M.; De Tullio, R.; Pedrazzi, M.; Milanese, M.; Bonifacino, T.; Bonanno, G.; Salamino, F.; Pontremoli, S.; Melloni, E. Role of calpain-1 in the early phase of experimental ALS. Arch. Biochem. Biophys. 2014, 562, 1–8.

15. Hadzhieva, M.; Kirches, E.; Wilisch-Neumann, A.; Pachow, D.; Wallesch, M.; Schoenfeld, P.; Paege, I.; Vielhaber, S.; Petri, S.; Keilhoff, G.; et al. Dysregulation of iron protein expression in the G93A model of amyotrophic lateral sclerosis. Neuroscience 2013, 230, 94–101.

16. Burlando, B.; Milanese, M.; Giordano, G.; Bonifacino, T.; Ravera, S.; Blanchini, F.; Bonanno, G. A multistationary loop model of ALS unveils critical molecular interactions involving mitochondria and glucose metabolism. PLoS ONE 2020, 15, e0244234.

17. Obrador, E.; Salvador, R.; López-Blanch, R.; Jihad-Jebbar, A.; Vallés, S.L.; Estrela, J.M. Oxidative Stress, Neuroinflammation and Mitochondria in the Pathophysiology of Amyotrophic Lateral Sclerosis. Antioxidants 2020, 9, 901.

18. Morfini, G.A.; Bosco, D.A.; Brown, H.; Gatto, R.; Kaminska, A.; Song, Y.; Molla, L.; Baker, L.; Marangoni, M.N.; Berth, S.; et al. Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase. PLoS ONE 2013, 8, e65235.

19. Gibbs, K.L.; Kalmar, B.; Rhymes, E.R.; Fellows, A.D.; Ahmed, M.; Whiting, P.; Davies, C.H.; Greensmith, L.; Schiavo, G. Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS. Cell Death Dis. 2018, 9, 596.

20. Burk, K.; Pasterkamp, R.J. Disrupted neuronal trafficking in amyotrophic lateral sclerosis. Acta Neuropathol. 2019, 137, 859–877.

21. Suzuki, N.; Akiyama, T.; Warita, H.; Aoki, M. Omics Approach to Axonal Dysfunction of Motor Neurons in Amyotrophic Lateral Sclerosis (ALS). Front. Neurosci. 2020, 14, 194.

22. Brites, D.; Vaz, A.R. Microglia centered pathogenesis in ALS: Insights in cell interconnectivity. Front. Cell. Neurosci. 2014, 8, 117.

23. Chiarotto, G.B.; Cartarozzi, L.P.; Perez, M.; Biscola, N.P.; Spejo, A.B.; Gubert, F.; França Junior, M.; Mendez-Otero, R.; de Oliveira, A.L.R. Tempol improves neuroinflammation and delays motor dysfunction in a mouse model (SOD1(G93A)) of ALS. J. Neuroinflamm. 2019, 16, 218.

24. Zetterström, P.; Stewart, H.G.; Bergemalm, D.; Jonsson, P.A.; Graffmo, K.S.; Andersen, P.M.; Brännström, T.; Oliveberg, M.; Marklund, S.L. Soluble misfolded subfractions of mutant superoxide dismutase-1s are enriched in spinal cords throughout life in murine ALS models. Proc. Natl. Acad. Sci. USA 2007, 104, 14157–14162.

25. Ramesh, N.; Pandey, U.B. Autophagy Dysregulation in ALS: When Protein Aggregates Get Out of Hand. Front. Mol. Neurosci. 2017, 10, 263.

26. Bendotti, C.; Marino, M.; Cheroni, C.; Fontana, E.; Crippa, V.; Poletti, A.; De Biasi, S. Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: Implication for protein aggregation and immune response. Prog. Neurobiol. 2012, 97, 101–126.

27. Yerbury, J.J.; Farrawell, N.E.; McAlary, L. Proteome Homeostasis Dysfunction: A Unifying Principle in ALS Pathogenesis. Trends Neurosci. 2020, 43, 274–284.

28. Atkin, J.D.; Farg, M.A.; Walker, A.K.; McLean, C.; Tomas, D.; Horne, M.K. Endoplasmic reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic lateral sclerosis. Neurobiol. Dis. 2008, 30, 400–407.

29. Jaronen, M.; Goldsteins, G.; Koistinaho, J. ER stress and unfolded protein response in amyotrophic lateral sclerosis-a controversial role of protein disulphide isomerase. Front. Cell. Neurosci. 2014, 8, 402.

30. Vandoorne, T.; De Bock, K.; Van Den Bosch, L. Energy metabolism in ALS: An underappreciated opportunity? Acta Neuropathol. 2018, 135, 489–509.

31. Obrador, E.; Salvador-Palmer, R.; López-Blanch, R.; Jihad-Jebbar, A.; Vallés, S.L.; Estrela, J.M. The Link between Oxidative Stress, Redox Status, Bioenergetics and Mitochondria in the Pathophysiology of ALS. Int. J. Mol. Sci. 2021, 22, 6352.

32. Ravera, S.; Torazza, C.; Bonifacino, T.; Provenzano, F.; Rebosio, C.; Milanese, M.; Usai, C.; Panfoli, I.; Bonanno, G. Altered glucose catabolism in the presynaptic and perisynaptic compartments of SOD1(G93A) mouse spinal cord and motor cortex indicates that mitochondria are the site of bioenergetic imbalance in ALS. J. Neurochem. 2019, 151, 336–350.

33. Volkening, K.; Leystra-Lantz, C.; Yang, W.; Jaffee, H.; Strong, M.J. Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). Brain Res. 2009, 1305, 168–182.

34. Droppelmann, C.A.; Campos-Melo, D.; Ishtiaq, M.; Volkening, K.; Strong, M.J. RNA metabolism in ALS: When normal processes become pathological. Amyotroph. Lateral Scler. Front. Degener. 2014, 15, 321–336.

35. Gentile, F.; Scarlino, S.; Falzone, Y.M.; Lunetta, C.; Tremolizzo, L.; Quattrini, A.; Riva, N. The Peripheral Nervous System in Amyotrophic Lateral Sclerosis: Opportunities for Translational Research. Front. Neurosci. 2019, 13, 601.

36. Filipi, T.; Hermanova, Z.; Tureckova, J.; Vanatko, O.; Anderova, A.M. Glial Cells-The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. J. Clin. Med. 2020, 9, 261.

37. Crabé, R.; Aimond, F.; Gosset, P.; Scamps, F.; Raoul, C. How Degeneration of Cells Surrounding Motoneurons Contributes to Amyotrophic Lateral Sclerosis. Cells 2020, 9, 2550.

38. Abramzon, Y.A.; Fratta, P.; Traynor, B.J.; Chia, R. The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Front. Neurosci. 2020, 14, 42.

39. Boylan, K. Familial Amyotrophic Lateral Sclerosis. Neurol. Clin. 2015, 33, 807–830.

40. Mejzini, R.; Flynn, L.L.; Pitout, I.L.; Fletcher, S.; Wilton, S.D.; Akkari, P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019, 13, 1310.

41. Shatunov, A.; Al-Chalabi, A. The genetic architecture of ALS. Neurobiol. Dis. 2021, 147, 105156.

42. Zou, Z.-Y.; Zhou, Z.-R.; Che, C.-H.; Liu, C.-Y.; He, R.-L.; Huang, H.-P. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 2017, 88, 540–549.

43. Shepheard, S.R.; Parker, M.D.; Cooper-Knock, J.; Verber, N.S.; Tuddenham, L.; Heath, P.; Beauchamp, N.; Place, E.; Sollars, E.S.A.; Turner, M.R.; et al. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2021, 92, 510–518.

44. Grad, L.I.; Cashman, N.R. Prion-like activity of Cu/Zn superoxide dismutase: Implications for amyotrophic lateral sclerosis. Prion 2014, 8, 33–41.

45. Chen, Q.; Zhou, J.; Huang, C.; Huang, B.; Bi, F.; Zhou, H.; Xiao, B. Temporal Expression of Mutant TDP-43 Correlates with Early Amyotrophic Lateral Sclerosis Phenotype and Motor Weakness. Curr. Neurovasc. Res. 2018, 15, 3–9.

46. Kabashi, E.; Valdmanis, P.N.; Dion, P.; Spiegelman, D.; McConkey, B.J.; Vande Velde, C.; Bouchard, J.-P.; Lacomblez, L.; Pochigaeva, K.; Salachas, F.; et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008, 40, 572–574.

47. Ederle, H.; Dormann, D. TDP-43 and FUS en route from the nucleus to the cytoplasm. FEBS Lett. 2017, 591, 1489–1507.

48. Ciryam, P.; Lambert-Smith, I.A.; Bean, D.M.; Freer, R.; Cid, F.; Tartaglia, G.G.; Saunders, D.N.; Wilson, M.R.; Oliver, S.G.; Morimoto, R.I.; et al. Spinal motor neuron protein supersaturation patterns are associated with inclusion body formation in ALS. Proc. Natl. Acad. Sci. USA 2017, 114, E3935–E3943.

49. Wood, A.; Gurfinkel, Y.; Polain, N.; Lamont, W.; Lyn Rea, S. Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD. Int. J. Mol. Sci. 2021, 22, 4705.

50. Kwiatkowski, T.J.J.; Bosco, D.A.; Leclerc, A.L.; Tamrazian, E.; Vanderburg, C.R.; Russ, C.; Davis, A.; Gilchrist, J.; Kasarskis, E.J.; Munsat, T.; et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323, 1205–1208.

51. Hewitt, C.; Kirby, J.; Highley, J.R.; Hartley, J.A.; Hibberd, R.; Hollinger, H.C.; Williams, T.L.; Ince, P.G.; McDermott, C.J.; Shaw, P.J. Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 2010, 67, 455–461.

52. Vance, C.; Rogelj, B.; Hortobágyi, T.; De Vos, K.J.; Nishimura, A.L.; Sreedharan, J.; Hu, X.; Smith, B.; Ruddy, D.; Wright, P.; et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009, 323, 1208–1211.

53. DeJesus-Hernandez, M.; Mackenzie, I.R.; Boeve, B.F.; Boxer, A.L.; Baker, M.; Rutherford, N.J.; Nicholson, A.M.; Finch, N.A.; Flynn, H.; Adamson, J.; et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72, 245–256.

54. McGoldrick, P.; Zhang, M.; van Blitterswijk, M.; Sato, C.; Moreno, D.; Xiao, S.; Zhang, A.B.; McKeever, P.M.; Weichert, A.; Schneider, R.; et al. Unaffected mosaic C9orf72 case: RNA foci, dipeptide proteins, but upregulated C9orf72 expression. Neurology 2018, 90, e323–e331.

55. Pang, W.; Hu, F. Cellular and physiological functions of C9ORF72 and implications for ALS/FTD. J. Neurochem. 2021, 157, 334–350.

56. Jiang, L.; Zhang, T.; Lu, K.; Qi, S. The progress in C9orf72 research: ALS/FTD pathogenesis, functions and structure. Small GTPases 2021, 1–21.

57. van Blitterswijk, M.; van Es, M.A.; Koppers, M.; van Rheenen, W.; Medic, J.; Schelhaas, H.J.; van der Kooi, A.J.; de Visser, M.; Veldink, J.H.; van den Berg, L.H. VAPB and C9orf72 mutations in 1 familial amyotrophic lateral sclerosis patient. Neurobiol. Aging 2012, 33, e1–e4.

58. Gitler, A.D.; Tsuiji, H. There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS. Brain Res. 2016, 1647, 19–29.

59. Le Gall, L.; Anakor, E.; Connolly, O.; Vijayakumar, U.G.; Duddy, W.J.; Duguez, S. Molecular and Cellular Mechanisms Affected in ALS. J. Pers. Med. 2020, 10, 101.

60. Bruijn, L.I.; Beal, M.F.; Becher, M.W.; Schulz, J.B.; Wong, P.C.; Price, D.L.; Cleveland, D.W. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide d. Proc. Natl. Acad. Sci. USA 1997, 94, 7606–7611.

61. Bruijn, L.I.; Becher, M.W.; Lee, M.K.; Anderson, K.L.; Jenkins, N.A.; Copeland, N.G.; Sisodia, S.S.; Rothstein, J.D.; Borchelt, D.R.; Price, D.L.; et al. ALS-linked SOD1 mutant G85R mediates

damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997, 18, 327–338.

62. Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O'Regan, J.P.; Deng, H.X. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362, 59–62.

63. Ezzi, S.A.; Urushitani, M.; Julien, J.-P. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J. Neurochem. 2007, 102, 170–178.

64. Chen, K.; Bennett, S.A.; Rana, N.; Yousuf, H.; Said, M.; Taaseen, S.; Mendo, N.; Meltser, S.M.; Torrente, M.P. Neurodegenerative Disease Proteinopathies Are Connected to Distinct Histone Post-translational Modification Landscapes. ACS Chem. Neurosci. 2018, 9, 938–948.

65. Jhanji, R.; Behl, T.; Sehgal, A.; Bungau, S. Mitochondrial dysfunction and traffic jams in amyotrophic lateral sclerosis. Mitochondrion 2021, 58, 102–110.

66. Liu, Y.-J.; Tsai, P.-Y.; Chern, Y. Energy Homeostasis and Abnormal RNA Metabolism in Amyotrophic Lateral Sclerosis. Front. Cell. Neurosci. 2017, 11, 126.

67. Piancone, F.; La Rosa, F.; Marventano, I.; Saresella, M.; Clerici, M. The Role of the Inflammasome in Neurodegenerative Diseases. Molecules 2021, 26, 953.

68. Leblond, C.S.; Kaneb, H.M.; Dion, P.A.; Rouleau, G.A. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp. Neurol. 2014, 262, 91–101.

69. Chia, R.; Chiò, A.; Traynor, B.J. Novel genes associated with amyotrophic lateral sclerosis: Diagnostic and clinical implications. Lancet. Neurol. 2018, 17, 94–102.

70. Schram, S.; Loeb, J.A.; Song, F. Disease propagation in amyotrophic lateral sclerosis (ALS): An interplay between genetics and environment. J. Neuroinflamm. 2020, 17, 175.

71. Spencer, P.S.; Lagrange, E.; Camu, W. ALS and environment: Clues from spatial clustering? Rev. Neurol. 2019, 175, 652–663.

72. Babin, P.J.; Goizet, C.; Raldúa, D. Zebrafish models of human motor neuron diseases: Advantages and limitations. Prog. Neurobiol. 2014, 118, 36–58.

73. Philips, T.; Rothstein, J.D. Rodent Models of Amyotrophic Lateral Sclerosis. Curr. Protoc. Pharmacol. 2015, 69, 5.67.1–5.67.21.

74. Lutz, C. Mouse models of ALS: Past, present and future. Brain Res. 2018, 1693, 1–10.

75. Liguori, F.; Amadio, S.; Volonté, C. Where and Why Modeling Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2021, 22, 3977.

76. Albert C. Ludolph; Caterina Bendotti; Eran Blaugrund; Bastian Hengerer; Jean-Philippe Löffler; Joanne Martin; Vincent Meininger; Thomas Meyer; Saliha Moussaoui; Wim Robberecht; et

al.Sean ScottVincenzo SilaniLeonard H. Van Den BergENMC GROUP FOR THE ESTABLISHMENT OF Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop. *Amyotrophic Lateral Sclerosis* **2007**, *8*, 217-223, 10.1080/17482960701292837.

77. John C McGrath; Elspeth M McLachlan; Rolf Zeller; Transparency in Research involving Animals: The Basel Declaration and new principles for reporting research in BJP manuscripts. *British Journal of Pharmacology* **2015**, *172*, 2427-2432, 10.1111/bph.12956.